DOCSLIB.ORG

Patient Focused Disease State and Assistance Programs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patient Focused Disease State and Assistance Programs Patient Focused Disease State and Assistance Programs Medication Medication Toll-free Brand (Generic) Website number Additional Resources Allergy/Asthma Xolair (omalizumab) xolair.com 1-866-4-XOLAIR lung.org Cardiovascular Pradaxa (dabigatran) pradaxa.com 877-481-5332 heart.org Praluent (alirocumab) praluent.com 844-PRALUENT thefhfoundation.org Repatha (evolocumab) repatha.com 844-REPATHA Tikosyn (dofetilide) tikosyn.com 800-879-3477 Crohn’s Disease Cimzia (certolizumab pegol) cimzia.com 866-4-CIMZIA crohnsandcolitis.com Humira (adalimumab) humira.com 800-4-HUMIRA crohnsforum.com Stelara (ustekinumab) stelarainfo.com 877-STELARA Dermatology Cosentyx (secukinumab) cosentyx.com 844-COSENTYX psoriasis.org Dupixent (dupilumab) dupixent.com 844-DUPIXENT nationaleczema.org Enbrel (etanercept) enbrel.com 888-4-ENBREL Humira (adalimumab) humira.com 800-4-HUMIRA Otezla (apremilast) otezla.com 844-4-OTEZLA Stelara (ustekinumab) stelarainfo.com 877-STELARA Taltz (ixekizumab) taltz.com 800-545-5979 Hematology Aranesp (darbepoetin alfa) aranesp.com 805-447-1000 chemocare.com Granix (filgrastim) granixrx.com 888-4-TEVARX hematology.org Jadenu (deferasirox) jadenu.com 888-282-7630 Neulasta (pegfilgrastim) neulasta.com 800-77-AMGEN Neupogen (filgrastim) neupogen.com 800-77-AMGEN Nivestym (filgrastim) nivestym.com 800-879-3477 Zarxio (filgrastim) zarxio.com 800-525-8747 Zytiga (abiraterone) zytiga.com 800-JANSSEN Hepatitis B Baraclude (entecavir) baraclude.com 800-321-1335 cdc.gov Viread (tenofovir disoproxil viread.com 800-GILEAD-5 hepb.org fumarate) Hepatitis C Epclusa epclusa.com 844-4-EPCLUSA cdc.gov (sofosbuvir/velpatasvir) hepcliverfoundation.org Harvoni harvoni.com 855-7-MYPATH (ledipasvir/sofosbuvir) HIV Biktarvy biktarvy.com 800-226-2056 HIV.gov (bictegravir/emtricitabine/ niaid.nih.gov tenofovir alafenamide) aidsinfo.nih.gov Descovy (emtricitabine/ descovy.com 800-226-2056 AIDSUnited.org tenofovir alafenamide) Genvoya (elvitegravir/ genvoya.com 800-GILEAD-5 cobicistat/emtricitabine/ tenofovir alafenamide) Medication Medication Toll-free Brand (Generic) Website number Additional Resources HIV continued Odesfsey (emtricitabine/ odefsey.com 800-226-2056 HIV.gov rilpivirine/tenofovir niaid.nih.gov alafenamide) aidsinfo.nih.gov Symtuza (darunavir/ symtuza.com 800-JANSSEN AIDSUnited.org cobicistat/emtricitabine/ tenofovir alafenamide) Tivicay (dolutegravir) us.tivicay.com 844-588-3288 Triumeq (abacavir/ us.triumeq.com 844-588-3288 dolutegravir/lamivudine) Truvada (emtricitabine/ truvada.com 800-226-2056 tenofovir disoproxil) Viread (tenofovir disoproxil viread.com 800-GILEAD-5 fumarate) Migraine Aimovig (erenumab) aimovig.com 833-246-6844 migraineresearchfoundation.org Ajovy (fremanezumab) ajovy.com 888-438-8279 Emgality (galcanezumab) emgality.com 866-576-9144 Multiple Sclerosis Copaxone (glatiramer) copaxone.com 800-877-8100 msfocus.org Gilenya (fingolimod) gilenya.com 800-GILENYA Rebif (interferon beta-1a) rebif.com 877-447-3243 Oncology Afinitor (everolimus) us.afinitor.com 888-669-6682 cancer.gov Arimidex (anastrazole) arimidex.com 800-434-1121 cancer.org Aromasin (exemestane) aromasin.com 800-879-3477 chemocare.com Calquence (acalabrutinib) calquence.com 800-236-9933 Erleada (apalutamide) erleada.com 833-ERLEADA Imbruvica (ibrutinib) imbruvica.com 877-877-3536 Lupron (leuprolide) lupron.com 800-222-6885 Ninlaro (ixazomib) ninlaro.com 844-T1POINT Purixan (mercaptopurine) purixan-us.com 888-470-0578 Tasigna (nilotinib) us.tasigna.com 877-577-7756 Temodar (temozolomide) temodar.com 877-888-4231 Tykerb (lapatinib) us.tykerb.com 888-NOW-NOVA Venclexta (venetoclex) venclexta.com 800-633-9110 Xeloda (capecitabine) gene.com/patients/med 877-436-3683 icines/xeloda Xtandi (enzalutamide) xtandi.com 800-727-7003 Zejula (niraparib) zejula.com 888-825-5249 Zydelig (idelalisib) zydelig.com 800-GILEAD-5 Osteoporosis Forteo (teriparatide) forteo.com 866-4-FORTEO iofbonehealth.org Prolia (denosumab) prolia.com 800-772-6436 nof.org Respiratory Syncytial Virus Infection (RSV) Synagis (palivizumab) synagis.com 877-633-4411 lung.org Medication Medication Toll-free Brand (Generic) Website number Additional Resources Rheumatoid Arthritis Cimzia (certolizumab pegol) cimzia.com 866-4-CIMZIA rheumatoidarthritis.org Enbrel (etanercept) enbrel.com 888-4-ENBREL Humira (adalimumab) humira.com 800-4-HUMIRA Orencia (abatacept) orencia.com 800-ORENCIA Otezla (apremilast) otezla.com 844-4-OTEZLA Stelara (ustekinumab) stelarainfo.com 877-STELARA Xeljanz (tofacitinib) xeljanz.com 855-4-XELJANZ Transplant Afinitor (everolimus) us.afinitor.com 888-669-6682 transplantliving.org Cellcept (mycophenolate cellcept.com 888-835-2555 myast.org mofetil) srtr.org Envarsus XR (tacrolimus) envarsusxr.com 844-835-6947 Myfortic (mycophenolic acid) myfortic.com 888-669-6682 Neoral (cyclosporine pharm.us.novartis.com 888-NOW-NOVA modified) Prograf (tacrolimus) prograf.com 800-727-7003 Women’s Health Lupron (leuprolide) lupron.com 800-222-6885 womenshealth.gov Ovidrel (chorionic emdseronofertility.com 888-275-7376 gonadotropin) Miscellaneous Medication Information Resources • Center for Disease Control and Prevention - List of Diseases and Conditions • National Institutes of Health - Health Information • Medline Plus • Safe Medication – Drug Information • National Council on Patient Information and Education • Consumer Med Safety Financial Assistance Programs Patient Assistance Network Foundation panfoundation.org 866-316-7263 Health Well Foundation healthwellfoundation.org 800-675-8416 Patient Advocate Foundation patientadvocate.org 800-532-5274 The Assistance Fund tafcares.org 855-845-3663 Co-pay Relief copays.org 866-512-3861 *If you would like more information about any medications or financial assistance programs, please contact the Sparrow Specialty Pharmacy at (517) 364-2720* .
Load more

Recommended publications
  • Us 8530498 B1 3
    USOO853 0498B1 (12) UnitedO States Patent (10) Patent No.: US 8,530,498 B1 Zeldis (45) Date of Patent: *Sep. 10, 2013 (54) METHODS FORTREATING MULTIPLE 5,639,476 A 6/1997 OShlack et al. MYELOMAWITH 5,674,533 A 10, 1997 Santus et al. 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL- 395 A 22 N. 2-YL)PIPERIDINE-2,6-DIONE 5,731,325 A 3/1998 Andrulis, Jr. et al. 5,733,566 A 3, 1998 Lewis (71) Applicant: Celgene Corporation, Summit, NJ (US) 5,798.368 A 8, 1998 Muller et al. 5,874.448 A 2f1999 Muller et al. (72) Inventor: Jerome B. Zeldis, Princeton, NJ (US) 5,877,200 A 3, 1999 Muller 5,929,117 A 7/1999 Muller et al. 5,955,476 A 9, 1999 Muller et al. (73) Assignee: Celgene Corporation, Summit, NJ (US) 6,020,358 A 2/2000 Muller et al. - 6,071,948 A 6/2000 D'Amato (*) Notice: Subject to any disclaimer, the term of this 6,114,355 A 9, 2000 D'Amato patent is extended or adjusted under 35 SS f 1939. All et al. U.S.C. 154(b) by 0 days. 6,235,756 B1 5/2001 D'Amatoreen et al. This patent is Subject to a terminal dis- 6,281.230 B1 8/2001 Muller et al. claimer 6,316,471 B1 1 1/2001 Muller et al. 6,326,388 B1 12/2001 Man et al. 6,335,349 B1 1/2002 Muller et al. (21) Appl. No.: 13/858,708 6,380.239 B1 4/2002 Muller et al.
    [Show full text]
  • The Change of Fingolimod Patient Profiles Over Time
    Journal of Personalized Medicine Article The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0 Tjalf Ziemssen 1,* and Ulf Schulze-Topphoff 2 1 Zentrum für Klinische Neurowissenschaften, Universitätsklinikum Carl Gustav Carus, D-01307 Dresden, Germany 2 Novartis Pharma GmbH, D-90429 Nuremberg, Germany; [email protected] * Correspondence: [email protected] Abstract: (1) Background: Fingolimod (Gilenya®) was the first oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS). Since its approval, the treatment landscape has changed enormously. (2) Methods: Data of PANGAEA and PANGAEA 2.0, two German real-world studies, were descriptively analysed for possible evolution of patient profiles and treatment behavior. Both are prospective, multi-center, non-interventional, long-term studies on fingolimod use in RRMS in real life. Data of 4229 PANGAEA patients (recruited 2011–2013) and 2441 PANGAEA 2.0 patients (recruited 2015–2018) were available. Baseline data included demographics, RRMS characteristics and disease severity. (3) Results: The mean age of PANGAEA and PANGAEA 2.0 patients was similar (38.8 vs. 39.2 years). Patients in PANGAEA 2.0 had shorter disease duration (7.1 vs. 8.2 years) and fewer relapses in the year before baseline (1.2 vs. 1.6). Disease severity at baseline estimated by Citation: Ziemssen, T.; EDSS and SDMT was lower in PANGAEA 2.0 patients compared to PANGAEA (EDSS difference Schulze-Topphoff, U. The Change of 1.0 points; SDMT difference 3.3 points). (4) Conclusions: The results hint at an influence of changes in Fingolimod Patient Profiles over the treatment guidelines and the label on fingolimod patients profiles over time.
    [Show full text]
  • Multinational Evaluation of Mycophenolic Acid, Tacrolimus
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE providedORIGINAL by University of QueenslandPAPER eSpace ISSN 1425-9524 © Ann Transplant, 2016; 21: 1-11 DOI: 10.12659/AOT.895664 Received: 2015.08.15 Accepted: 2015.09.01 Multinational Evaluation of Mycophenolic Published: 2016.01.05 Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization Authors’ Contribution: ABCDEF Kyle M. Gardiner School of Pharmacy, University of Queensland, Brisbane, QLD, Australia Study Design A ACDEF Susan E. Tett Data Collection B Statistical Analysis C ACDEF Christine E. Staatz Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G Corresponding Author: Christine E. Staatz, e-mail: [email protected] Source of support: Departmental funding only Background: Increasing immunosuppressant utilization and expenditure is a worldwide challenge as more people success- fully live with transplanted organs. Our aims were to characterize utilization of mycophenolate, tacrolimus, cy- closporin, sirolimus, and everolimus in Australian transplant recipients from 2007 to 2013; to identify specific patterns of usage; and to compare Australian utilization with Norwegian, Danish, Swedish, and the Netherlands use. Material/Methods: Australian utilization and expenditure data were captured through national Pharmaceutical Benefits Scheme and Highly Specialized Drug administrative databases. Norwegian, Danish, Swedish, and the Netherlands uti- lization were retrieved from their healthcare databases. Utilization was compared as defined daily dose per 1000 population per day (DDD/1000 population/day). Data on kidney transplant recipients, the predominant patient group prescribed these medicines, were obtained from international transplant registries. Results: From 2007–2013 Australian utilization of mycophenolic acid, tacrolimus and everolimus increased 2.7-fold, 2.2- fold, and 2.3-fold, respectively.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22-527 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number 22-527 Priority or Standard P Submit Date 12-21-2009 Received Date 12-21-2009 PDUFA Goal Date 9-21-2010 Division / Office FDA/ODE1 Reviewer Name Heather D. Fitter Review Completion Date August 26, 2010 Established Name Fingolimod (Proposed) Trade Name Gilenya Therapeutic Class S1P receptor modulator Applicant Novartis Formulation(s) Oral tablets Dosing Regimen 0.5 mg Indication(s) To reduce the frequency of relapses and delay the progression of disability in relapsing MS Intended Population(s) Relapsing Multiple Sclerosis Template Version: March 6, 2009 Clinical Review Heather D. Fitter, M.D. NDA 22-527 Fingolimod Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT......................................... 7 1.1 Recommendation on Regulatory Action ............................................................. 7 1.2 Risk Benefit Assessment.................................................................................... 8 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 8 2.1 Product Information ............................................................................................ 9 2.2 Table of Currently Available Treatments for the Proposed Indication................. 9 2.3 Availability of Proposed Active Ingredient in the United States ........................ 12 2.4 Important Safety Issues with Consideration to Related Drugs.........................
    [Show full text]
  • WHO Drug Information Vol 22, No
    WHO Drug Information Vol 22, No. 1, 2008 World Health Organization WHO Drug Information Contents Challenges in Biotherapeutics Miglustat: withdrawal by manufacturer 21 Regulatory pathways for biosimilar Voluntary withdrawal of clobutinol cough products 3 syrup 22 Pharmacovigilance Focus Current Topics WHO Programme for International Drug Proposed harmonized requirements: Monitoring: annual meeting 6 licensing vaccines in the Americas 23 Sixteen types of counterfeit artesunate Safety and Efficacy Issues circulating in South-east Asia 24 Eastern Mediterranean Ministers tackle Recall of heparin products extended 10 high medicines prices 24 Contaminated heparin products recalled 10 DacartTM development terminated and LapdapTM recalled 11 ATC/DDD Classification Varenicline and suicide attempts 11 ATC/DDD Classification (temporary) 26 Norelgestromin-ethynil estradiol: infarction ATC/DDD Classification (final) 28 and thromboembolism 12 Emerging cardiovascular concerns with Consultation Document rosiglitazone 12 Disclosure of transdermal patches 13 International Pharmacopoeia Statement on safety of HPV vaccine 13 Cycloserine 30 IVIG: myocardial infarction, stroke and Cycloserine capsules 33 thrombosis 14 Erythropoietins: lower haemoglobin levels 15 Recent Publications, Erythropoietin-stimulating agents 15 Pregabalin: hypersensitivity reactions 16 Information and Events Cefepime: increased mortality? 16 Assessing the quality of herbal medicines: Mycophenolic acid: pregnancy loss and contaminants and residues 36 congenital malformation 17 Launch
    [Show full text]
  • Analysis of Changes in Disease Modifying Treatment in The
    Abstract number 4CPS-109 ATC code: L04 - Immunosuppressive agents ANALYSIS OF CHANGES IN DISEASE MODIFYING TREATMENT IN THE MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS Arancón Pardo A1, Sobrino Jiménez C1, Rodríguez Martín E1, Bilbao Gómez-Martino C1, Villamañán Bueno E1, Jiménez-Nácher I1, Moreno Ramos F1, González Fernández A1, Moreno Palomino M1, García-Trevijano M1, Herrero Ambrosio A1 1Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain. BACKGROUND AND IMPORTANCE •Currently, several disease modifying drugs are approved for multiple sclerosis (MS). IFNβ-1b, IFNβ-1a, pegIFNβ-1a, glatiramer acetate, teriflunomide and dimethylfumarate are indicated for first-line therapy. Second-line treatment includes natalizumab, fingolimod, alemtuzumab, cladribine and ocrelizumab. When disease progresses, modifications between first-line drugs or switch to a second-line drug are proposed. It is essential to know their efficacy and security profiles, in order to decide which is the best option for each patient. AIM AND OBJECTIVES •To assess the reasons for changes in disease modifying drugs in MS patients in routine clinical practice. MATERIAL AND METHODS •We included patients with MS who changed their treatment between 23rd May 2018 and 26th March 2019. •The collected data were: Disease modifying drugs Reasons for treatment Duration of initial therapy before and after the modification modification RESULTS •42 patients had any treatment modification during the study period. •26 (62%) were women and mean age was 47 years (SD 9.3). •Median duration of previous treatment was 44 months (3-282). •Previous treatment was a first-line drug in 34 patients (81%) and modified treatment was a first-line drug in 24 (57%).
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • The Breakthrough of Biosimilars: a Twist in the Narrative of Biological Therapy
    biomolecules Review The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy Eva Rahman Kabir 1,* , Shannon Sherwin Moreino 1 and Mohammad Kawsar Sharif Siam 1,2 1 Department of Pharmacy, BRAC University, Dhaka 1212, Bangladesh 2 Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK * Correspondence: [email protected] Received: 12 June 2019; Accepted: 20 August 2019; Published: 24 August 2019 Abstract: The coming wave of patent expiries of first generation commercialized biotherapeutical drugs has seen the global market open its doors to close copies of these products. These near perfect substitutes, which are termed as “biosimilars”, do not need to undergo intense clinical trials for their approval. However, they are mandated to produce identical similarity from their reference biologics in terms of clinical safety and efficacy. As such, these biosimilar products promise to foster unprecedented access to a wide range of life-saving biologics. However, seeing this promise be fulfilled requires the development of biosimilars to be augmented with product trust, predictable regulatory frameworks, and sustainable policies. It is vital for healthcare and marketing professionals to understand the critical challenges surrounding biosimilar use and implement informed clinical and commercial decisions. A proper framework of pharmacovigilance, education, and scientific exchange for biologics and biosimilars would ensure a dramatic rise in healthcare access and market sustainability. This paper seeks to collate and review all relevant published intelligence of the health and business potential of biosimilars. In doing so, it provides a visualization of the essential steps that are required to be taken for global biosimilar acceptance.
    [Show full text]
  • Hpra Drug Safety 66Th Newsletter Edition
    FEBRUARY 2015 HPRA DRUG SAFETY 66TH NEWSLETTER EDITION 3 Mycophenolate mofetil (CellCept) and 4 Direct Healthcare Professional In this Edition Mycophenolic acid (Myfortic) - New warnings Communications published on about the risks of hypogammaglobulinaemia the HPRA website since the last 1 Eligard (leuprorelin acetate depot injection) and bronchiectasis Drug Safety Newsletter - Risk of lack of efficacy due to incorrect reconstitution and administration process 4 Tecfidera (dimethyl fumarate) - Progressive Multifocal Leukoencephalopathy (PML) has 2 Beta interferons – Risk of thrombotic occurred in a patient with severe microangiopathy and nephrotic syndrome and prolonged lymphopenia Eligard (leuprorelin acetate depot injection) - Risk of lack of efficacy due to incorrect reconstitution and administration process Following identification of a signal and safe treatment of patients with It is available in six-monthly (45mg), of administration errors with Eligard prostate cancer. Lack of efficacy may three-monthly (22.5mg) and one- and concerns that such errors may occur due to incorrect reconstitution monthly (7.5mg) formulations. In impact on clinical efficacy, this issue of Eligard. the majority of patients, androgen was reviewed at EU level by the deprivation therapy (ADT) with Eligard Eligard is indicated for the treatment Pharmacovigilance Risk Assessment results in testosterone levels below the of hormone dependent advanced Committee (PRAC). A cumulative standard castration threshold (<50ng/ prostate cancer and for the treatment review of reported global cases dL; <1.7 nmol/L); and in most cases, of high risk localised and locally identified errors related to storage, patients reach testosterone levels advanced hormone dependent preparation and reconstitution of below <20ng/dL. prostate cancer in combination Eligard.
    [Show full text]
  • Forty-Sixth Annual MALTO Medicinal Chemistry & Pharmacognosy
    Forty-Sixth Annual MALTO Medicinal Chemistry & Pharmacognosy Meeting-in-Miniature May 20th – 22nd, 2019 Hosted by The Department of Pharmaceutical Sciences College of Pharmacy University of Tennessee Health Science Center, Memphis, TN A A O O M L M L T T 1 | Page 2019 MALTO Meeting At the University of Tennessee Health Science Center College of Pharmacy Table of Contents Page 2019 MALTO Contributors and Sponsors……………..………….……....4 2019 MALTO Executive Officers……………..……………..…………..…4 MALTO Board of Directors………………………………………..………5 MALTO 2019 Organizing Committee……………………………………..5 General Program…………………………………………………….……6-7 MALTO – A Brief History………………………………………………..8-9 A. Nelson Voldeng Memorial Lecture………………………...…….....10-11 Dr. Jeff Aubé, Fred Eshelman Distinguished Professor of Chemistry, The University of North Carolina Eshelman School of Pharmacy Biographical Information………………………………………..….11 Abstract………………………………………………………………12 History of The Robert A. Magarian Outstanding Podium Presentation Award ………………………..……………………………….…………13-15 History of The Thomas L. Lemke Outstanding Poster Presentation Award…………………………………………………………..… …….16-17 History of The Ronald F. Borne Outstanding Poster Presentation Award……………………………………………………………………18-19 Meeting Schedule for Monday, May 20th, 2019…………………….….…20 2 | Page Meeting Schedule for Tuesday, May 21st, 2019………………………20-26 Meeting Schedule for Wednesday, May 22nd, 2019…………………..27-28 Podium Presentation Abstracts………..……………………...………29-52 Poster Presentation Abstracts …………………..……….……………53-70 MALTO Primary Contacts………………………………………...….71-73
    [Show full text]
  • Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients
    Evidence Report/Technology Assessment Number 164 Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-02-0020 Task Order Leader: Parminder Raina, Ph.D. Director, McMaster University Evidence-based Practice Center Co-Principal Investigators: Mark Oremus, Ph.D. Johannes Zeidler, Ph.D., D.A.B.C.C. Authors: Mark Oremus, Ph.D. Johannes Zeidler, Ph.D., D.A.B.C.C. Mary H.H. Ensom, Pharm.D., F.A.S.H.P., F.C.C.P., F.C.S.H.P. Mina Matsuda-Abedini, M.D.C.M., F.R.C.P.C. Cynthia Balion, Ph.D., F.C.A.C.B. Lynda Booker, B.A. Carolyn Archer, M.Sc. Parminder Raina, Ph.D. AHRQ Publication No. 08-E006 February 2008 This report is based on research conducted by the McMaster University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0020). The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services.
    [Show full text]
  • The Real-World Patient Experience of Fingolimod and Dimethyl Fumarate
    Wicks et al. BMC Res Notes (2016) 9:434 DOI 10.1186/s13104-016-2243-8 BMC Research Notes RESEARCH ARTICLE Open Access The real‑world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis Paul Wicks1* , Lawrence Rasouliyan2, Bo Katic1, Beenish Nafees3, Emuella Flood3 and Rahul Sasané4 Abstract Background: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. Objectives: To compare patient-reported experiences of fingolimod and dimethyl fumarate. Methods: Adult relapsing-remitting multiple sclerosis patients treated with fingolimod or dimethyl fumarate were recruited from an online patient community and completed an online survey about treatment side effects, discon- tinuation, and satisfaction. Results: 281 patients in four groups completed the survey: currently receiving fingolimod (CF, N 61), currently receiving dimethyl fumarate (CDMF, N 129), discontinued fingolimod (DF, N 32) and discontinued= dimethyl fuma- rate (DDMF, N 59). Reasons for treatment= switch were to take oral treatment =(CF: 63.3 %, CDMF: 61.8 %), side effects of prior medication= (CF: 67.3 %, CDMF: 44.1 %) and lack of effectiveness of prior medication (CF: 38.8 %, CDMF: 31.4 %). Main reasons for discontinuation were side effects (DF: 46.9 %, DDMF: 67.8 %) and lack of effectiveness (DF: 25.0 %, DDMF: 15.3 %). CDMF patients had an increased risk of abdominal pain, flushing, diarrhea, and nausea. Treatment satisfaction was highest among CF patients followed by CDMF, DF, and then DDMF patients. Conclusions: Discontinuation was driven by experience of side effects. Patients currently taking dimethyl fumarate were more likely to experience a side effect versus patients currently taking fingolimod.
    [Show full text]